Posted by Defense World Staff on Jul 2nd, 2024
Nexalin Technology (NASDAQ:NXL – Get Free Report) is one of 76 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its peers? We will compare Nexalin Technology to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, dividends, analyst recommendations and profitability.
This is a breakdown of recent ratings for Nexalin Technology and its peers, as reported by MarketBeat.
As a group, “Electromedical equipment” companies have a potential upside of 27.31%. Given Nexalin Technology’s peers higher possible upside, analysts clearly believe Nexalin Technology has less favorable growth aspects than its peers.
This table compares Nexalin Technology and its peers gross revenue, earnings per share and valuation.
Nexalin Technology’s peers have higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This table compares Nexalin Technology and its peers’ net margins, return on equity and return on assets.
Nexalin Technology has a beta of 5.53, meaning that its share price is 453% more volatile than the S&P 500. Comparatively, Nexalin Technology’s peers have a beta of 12.70, meaning that their average share price is 1,170% more volatile than the S&P 500.
0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are held by institutional investors. 27.7% of Nexalin Technology shares are held by company insiders. Comparatively, 14.8% of shares of all “Electromedical equipment” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Nexalin Technology peers beat Nexalin Technology on 8 of the 10 factors compared.
(Get Free Report)
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for Nexalin Technology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Nexalin Technology and related companies with MarketBeat.com’s FREE daily email newsletter.
PROG Holdings, Inc. (NYSE:PRG) Receives Average Recommendation of “Moderate Buy” from Brokerages
MetLife (NYSE:MET) Downgraded by StockNews.com to Hold